Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

<h4>Background</h4> <p>Cross-resistance after first-line antiretroviral treatment (ART) failure is expected to impair activity of nucleoside-reverse-transcriptase-inhibitors (NRTIs) in second-line therapy, but evidence for effect on virological outcomes is limited.</p> <h...

Full description

Bibliographic Details
Main Authors:	Paton, N, Kityo, C, Thompson, J, Nankya, I, Bagenda, L, Hoppe, A, Hakim, J, Kambugu, A, van Oosterhout, J, Kinconco, M, Bertagnolio, S, Easterbrook, P, Mugyenyi, P, Walker, A
Format:	Journal article
Published:	Elsevier 2017

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Similar Items